Patent SG-11201809725T-A (SG)
Title: Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist
Inventor: NIROGI RAMAKRISHNA
IPC: A61P25/28
Filed: 2016-08-03
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111111111111111111111111111111111111111111111111111111111111111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/199072 Al 23 November 2017 (23.11.2017) WIPO I PCT (51) International Patent Classification: Serene Chambers, Road-5, Avenue — 7, Banjara Hills, Hy- A61K 31/13 (2006.01) A61P 25/28 (2006.01) derabad, Telangana 500034 (IN). A61K 31/496 (2006.01) (74) Agent: BHASIN, Gayatri et al.; Central Square, Suite - (21) International Application Number: 328, Plaza III, 20 Manoharlal Khurana Marg, Bara Hindu PCT/IB2016/054674 Rao (off Rani Jhansi Road), Delhi 110 006 (IN). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 03 August 2016 (03.08.2016) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (25) Filing Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, (26) Publication Language: English EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, (30) Priority Data: LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, 201641017203 18 May 2016 (18.05.2016) IN MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, (71) Applicant: SUVEN LIFE SCIENCES LIMITED PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, [IN/IN]; Serene Chambers, Road-5, Avenue — 7, Banjara SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, Hills, Hyderabad, Telangana 500034 (IN). UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (72) Inventors: NIROGI, Ramakrishna; Serene Chambers, (84) Designated States (unless otherwise indicated, for every Road-5, Avenue — 7, Banjara Hills, Hyderabad, Telangana kind of regional protection available): ARIPO (BW, GH, _ 500034 (IN). SHINDE, Anil Karbhari; Serene Cham- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, bers, Road-5, Avenue — 7, Banjara Hills, Hyderabad, Telan- UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, gana 500034 (IN). JAYARAJAN, Pradeep; Serene Cham- TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = bers, Road-5, Avenue — 7, Banjara Hills, Hyderabad, Telan- EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = gana 500034 (IN). BHYRAPUNENI, Gopinadh; Serene MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, _ Chambers, Road-5, Avenue — 7, Banjara Hills, Hyderabad, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, = Telangana 500034 (IN). KAMBHAMPATI, Ramasastri; KM, ML, MR, NE, SN, TD, TG). Serene Chambers, Road-5, Avenue — 7, Banjara Hills, Hy- _ derabad, Telangana 500034 (IN). JASTI, Venkateswarlu; = = (54) Title: COMBINATION OF PURE 5-HT6 RECEPTOR ANTAGONISTS WITH NMDA RECEPTOR ANTAGONIST = = — Figure la = = 0.8- a) -cs c 0.7- ._ a) - = = = > = 2 0.6- = ._ — E '= c.) 0.5- co in _ = 0.4 — Vehicle Compound 1 Vehicle Compound 1 Il 2 m L/kg, p.o. 1 mg/kg, p.o. 2 mL/kg, p.o. 1 mg/kg, p.o. Vehicle Vehicle Memantine, Memantine, el IN 2 m L/kg, p.o. 2 mL/kg, p.o. 0.3 mg/kg, p.o. 0.3 mg/kg, p.o. © Dala represents Mean ± SEM of discriminative index. *p<0.05 Vs vehicle (Kruskal-Wallis 0\ 0\ followed by Dunn's Multiple Comparison Tesl) N=8-11 1-1 IN 1-1 (57) : The present invention relates to pure 5-HT6 receptor antagonist or the pharmaceutically acceptable salt(s) thereof in C:::: ) combination with or as adjunct to NMDA receptor antagonist and their use in the treatment of cognitive disorders. The invention further el relates to the pharmaceutical composition containing the said combination. [Continued on next page] WO 2017/199072 Al MIDEDIMOMMIDIRMEMMICHIMONMOIIIMEMOE# Declarations under Rule 4.17: — as to applicant's entitlement to apply patent (Rule 4.17(H)) for and be granted a Published: — with international search report (Art. 21(3))